

# The Biochemical Society

## Speaker Highlight: Prof. Jean-Jacques Fournié



- Research focuses on immuno-oncology, predicting therapeutic responses of  $\gamma\delta$  T-lymphocytes in cancer treatment with a focus on lymphomas.
- He is a founder of the innate immunity company “Innate Pharms, SAS”, founded in 1999 and became director of the Cancer Research Centre of Toulouse in 2010.
- He has published just under 200 papers with over 8000 citations between them in Journals such as *Oncoimmunology*, *Frontiers in Immunology* and the *European Journal of Immunology*.

### Related Publications:

- Assessment of tumor-infiltrating TCRV $\gamma$ 9V $\delta$ 2  $\gamma\delta$  lymphocyte abundance by deconvolution of human cancers microarrays. *Oncoimmunology*.
- IL-33-expanded human V $\gamma$ 9V $\delta$ 2 T cells have anti-lymphoma effect in a mouse tumor model. *Eur J Immunol*.
- Distinctive features of tumor-infiltrating  $\gamma\delta$  T lymphocytes in human colorectal cancer. *Oncoimmunology*